Can oncologists add?

Marc E Lippman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the present study, rather convincing evidence for an alternative mechanism of antiestrogen action through a non-receptor-mediated pathway is provided. Antiestrogens are shown to alter cytotoxicity of melphalan and fluorouracil without themselves exerting growth inhibitory effects. While the mechanism(s) of this remain to be determined, these studies should provide several important caveats to clinical investigators. First, empirical drug combinations should not be assumed to increase activity. Whenever possible scheduling and drug combinations should be rationally explored in vitro and in animal models. Second, other molecular sites of action aside from the high-affinity estrogen receptor must clearly exist for antiestrogens and their role as targets for therapeutic intervention need to be explored. Whether these will turn out to be the ubiquitous but undefined antiestrogen binding sites previously described will await further study.

Original languageEnglish
Pages (from-to)698-699
Number of pages2
JournalJournal of Clinical Oncology
Volume7
Issue number6
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Drug Combinations
Melphalan
Fluorouracil
Estrogen Receptors
Animal Models
Binding Sites
Research Personnel
Oncologists
Growth
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lippman, M. E. (1989). Can oncologists add? Journal of Clinical Oncology, 7(6), 698-699.

Can oncologists add? / Lippman, Marc E.

In: Journal of Clinical Oncology, Vol. 7, No. 6, 01.01.1989, p. 698-699.

Research output: Contribution to journalArticle

Lippman, ME 1989, 'Can oncologists add?', Journal of Clinical Oncology, vol. 7, no. 6, pp. 698-699.
Lippman ME. Can oncologists add? Journal of Clinical Oncology. 1989 Jan 1;7(6):698-699.
Lippman, Marc E. / Can oncologists add?. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 6. pp. 698-699.
@article{7efcb4b37fb747cb98d954bb19980729,
title = "Can oncologists add?",
abstract = "In the present study, rather convincing evidence for an alternative mechanism of antiestrogen action through a non-receptor-mediated pathway is provided. Antiestrogens are shown to alter cytotoxicity of melphalan and fluorouracil without themselves exerting growth inhibitory effects. While the mechanism(s) of this remain to be determined, these studies should provide several important caveats to clinical investigators. First, empirical drug combinations should not be assumed to increase activity. Whenever possible scheduling and drug combinations should be rationally explored in vitro and in animal models. Second, other molecular sites of action aside from the high-affinity estrogen receptor must clearly exist for antiestrogens and their role as targets for therapeutic intervention need to be explored. Whether these will turn out to be the ubiquitous but undefined antiestrogen binding sites previously described will await further study.",
author = "Lippman, {Marc E}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "698--699",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Can oncologists add?

AU - Lippman, Marc E

PY - 1989/1/1

Y1 - 1989/1/1

N2 - In the present study, rather convincing evidence for an alternative mechanism of antiestrogen action through a non-receptor-mediated pathway is provided. Antiestrogens are shown to alter cytotoxicity of melphalan and fluorouracil without themselves exerting growth inhibitory effects. While the mechanism(s) of this remain to be determined, these studies should provide several important caveats to clinical investigators. First, empirical drug combinations should not be assumed to increase activity. Whenever possible scheduling and drug combinations should be rationally explored in vitro and in animal models. Second, other molecular sites of action aside from the high-affinity estrogen receptor must clearly exist for antiestrogens and their role as targets for therapeutic intervention need to be explored. Whether these will turn out to be the ubiquitous but undefined antiestrogen binding sites previously described will await further study.

AB - In the present study, rather convincing evidence for an alternative mechanism of antiestrogen action through a non-receptor-mediated pathway is provided. Antiestrogens are shown to alter cytotoxicity of melphalan and fluorouracil without themselves exerting growth inhibitory effects. While the mechanism(s) of this remain to be determined, these studies should provide several important caveats to clinical investigators. First, empirical drug combinations should not be assumed to increase activity. Whenever possible scheduling and drug combinations should be rationally explored in vitro and in animal models. Second, other molecular sites of action aside from the high-affinity estrogen receptor must clearly exist for antiestrogens and their role as targets for therapeutic intervention need to be explored. Whether these will turn out to be the ubiquitous but undefined antiestrogen binding sites previously described will await further study.

UR - http://www.scopus.com/inward/record.url?scp=0024320798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024320798&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 698

EP - 699

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -